Trevi to present phase 2a trial data on chronic cough treatment at ERS
PositiveFinancial Markets

Trevi Therapeutics is set to present promising data from its phase 2a trial on a new treatment for chronic cough at the upcoming European Respiratory Society (ERS) conference. This is significant as chronic cough affects millions and finding effective treatments can greatly improve quality of life for patients. The presentation could also attract attention from investors and healthcare professionals, potentially leading to further advancements in respiratory therapies.
— Curated by the World Pulse Now AI Editorial System